Literature DB >> 26755221

Pulmonary function tests in patients with Parkinson's disease: A case-control study.

L F Owolabi1, M Nagoda, M Babashani.   

Abstract

BACKGROUND: In Parkinson's disease (PD), morbidity and mortality are commonly caused by respiratory disorders from pulmonary function impairments. AIM: The study aims to evaluate pulmonary functions in a cohort of patients with PD in comparison with age- and sex-matched control.
METHODS: Pulmonary function test (PFT) was conducted using the Spirolab Spirometry kit, and results of forced vital capacity (VC), forced expiratory volume 1 (FEV1), FEV1/VC, and peak expiratory flow rate (PEFR) were obtained from 78 PD patients and 78 healthy controls.
RESULTS: A total of 78 patients and 78 age- and sex-matched control comprising 60 (76.9%) males and 18 (23.1%) females were evaluated. The mean age ± standard deviation of the patients were 62.32 ± 8.67 and 62.31 ± 8.66, respectively; the difference in their age was not statistically significant (P = 0.993). The majority (38.5%) of the patients was in stage II of Hoehn and Yahr of PD. Vital capacity (VC) in PD patients and control was 2.481 and 3.106; the difference was statistically significant (P < 0.0001). The mean FEV1 in PD patients and control were 1.887 and 2.494; the difference was statistically significant (P < 0.0001). The mean FEV1/VC percent in PD patients and control were 75.812 and 80.303; the difference was statistically significant (P < 0.0001). The mean PEFR in PD patients and control were 45.58 and 67.46; the difference was statistically significant (P < 0.0001). Considering PD arm of the study, with the exception of FEV1/VC, there was significant negative correlation between all the parameters of PFT and patients age (VC, FEV1, PEFR, r = -422 and P = 0.0001, r = -391 and P = 0.0001, and r = -0.244 and P = 0.031, respectively).
CONCLUSION: In this study, the values of the evaluated PFTs (VC, FEV1, FEV1/VC, and PEFR) parameters were significantly lower in PD compared with age- and sex-matched control.

Entities:  

Mesh:

Year:  2016        PMID: 26755221     DOI: 10.4103/1119-3077.173714

Source DB:  PubMed          Journal:  Niger J Clin Pract            Impact factor:   0.968


  6 in total

Review 1.  Parkinson's disease in Nigeria: A review of published studies and recommendations for future research.

Authors:  Oluwafemi G Oluwole; Helena Kuivaniemi; Jonathan A Carr; Owen A Ross; Matthew O B Olaogun; Soraya Bardien; Morenikeji A Komolafe
Journal:  Parkinsonism Relat Disord       Date:  2018-12-08       Impact factor: 4.891

2.  Unraveling the Mechanisms Underlying Irregularities in Inspiratory Rhythm Generation in a Mouse Model of Parkinson's Disease.

Authors:  Luiz M Oliveira; Nathan A Baertsch; Thiago S Moreira; Jan-Marino Ramirez; Ana C Takakura
Journal:  J Neurosci       Date:  2021-04-16       Impact factor: 6.167

3.  Effect of Disease Severity on Respiratory Impedance in Parkinson's Disease.

Authors:  Meghashree Sampath; Achal Kumar Srivastava; Vinay Goyal; Ashok Kumar Jaryal; Kishore Kumar Deepak; Anjana Talwar
Journal:  Ann Neurosci       Date:  2020-11-09

Review 4.  Respiratory Abnormalities in Parkinson's Disease: What Do We Know from Studies in Humans and Animal Models?

Authors:  Katarzyna Kaczyńska; Magdalena Ewa Orłowska; Kryspin Andrzejewski
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

5.  Effects of an Aquatic Physical Exercise Program on Ventilatory Parameters in People with Parkinson's Disease.

Authors:  Bruna Yamaguchi; Dielise Debona Iucksch; Luis Henrique Paladini; Vera Lúcia Israel
Journal:  Parkinsons Dis       Date:  2022-08-31

6.  Respiratory Dysfunction in Parkinson's Disease: Relation with Dysautonomia.

Authors:  Meghashree Sampath; Geetanjali Bade; Vinay Goyal; Achal K Srivastava; Ashok K Jaryal; Kishore K Deepak; Anjana Talwar
Journal:  Ann Indian Acad Neurol       Date:  2022-04-06       Impact factor: 1.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.